Form 4: Ventyx CMO Acquires Shares via Employee Stock Plan

Ventyx Biosciences' Chief Medical Officer, Mark S. Forman, acquired 3,000 shares of common stock through the company's Employee Stock Purchase Plan.

Summary

• Mark S. Forman, Chief Medical Officer of Ventyx Biosciences, Inc. (VTYX), acquired 3,000 shares of common stock.
• The acquisition occurred on November 17, 2025, through the Ventyx Biosciences, Inc. 2021 Employee Stock Purchase Plan (ESPP).
• Shares were purchased at a price of $1.03 per share.
• The purchase price was based on 85% of the closing price on May 15, 2025, as per the 2021 ESPP terms.
• Following this transaction, Mark S. Forman beneficially owns 6,000 shares of common stock.
• This transaction is exempt under Rule 16b-3(c) of the Securities Exchange Act of 1934.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive. While an ESPP purchase is routine, it still represents an insider increasing their stake in the company, which can be interpreted as a sign of continued confidence. The discounted price is a positive for the employee.

Positives

• An insider, the Chief Medical Officer, is acquiring additional shares in the company, which can signal confidence in the company's future prospects.
• The acquisition was made at a discounted price of $1.03 per share, based on 85% of the closing price on May 15, 2025, providing a benefit to the employee.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider transactions, particularly those through employee stock purchase plans, are common across industries. While they indicate an employee's participation in company ownership, they are generally considered routine and do not typically reflect specific market-moving insights or strategic shifts, unlike open market purchases or sales.

Comparison to Industry Standards

• Employee Stock Purchase Plans (ESPPs) are a standard benefit offered by many publicly traded companies, including those in the biotechnology and pharmaceutical sectors, to encourage employee ownership.
• The discount offered (15% off the lower of the start or end period price, implied by 85% of a specific date's closing price) is typical for ESPP structures across various industries, aligning with common practices for such plans.

Related Party Transactions

• The acquisition of shares by the Chief Medical Officer through the company's 2021 Employee Stock Purchase Plan (ESPP) constitutes a transaction between an insider and the company, which is a common and pre-approved employee benefit.

Stakeholder Impact

• Shareholders: May view the insider purchase as a minor positive signal of management's continued alignment with shareholder interests.
• Employees: The ESPP provides a benefit to employees, allowing them to purchase company stock at a discount, fostering a sense of ownership and aligning their interests with the company's performance.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned acquisition of shares by a Chief Medical Officer through an Employee Stock Purchase Plan (ESPP). While insider buying can be a positive signal, ESPP purchases are typically not indicative of new, material information or a strong discretionary investment decision that would warrant a change in investment recommendation. It reflects a standard employee benefit and ongoing participation rather than a significant shift in investment thesis. Therefore, a 'hold' recommendation is appropriate, as this specific filing does not provide new information to alter an existing investment stance.

Keywords

Ventyx Biosciences, VTYX, Insider Transaction, Employee Stock Purchase Plan, ESPP, Common Stock, Mark S. Forman, Chief Medical Officer, Beneficial Ownership